Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India

Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) class of antidiabetic medication. High costs and GI side effects are the major limitations of its widespread use. Some patients who were on a 14 mg dose of oral semaglutide self-prescribed an alternate-day schedul...

Descripción completa

Detalles Bibliográficos
Autores principales: RoyChaudhuri, Soumyabrata, Majumder, Anirban, Mukherjee, Poulomi, Sanyal, Debmalya, Chakraborty, Soma, Chuyan, Susama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329815/
https://www.ncbi.nlm.nih.gov/pubmed/37431351
http://dx.doi.org/10.7759/cureus.40179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329815/
https://www.ncbi.nlm.nih.gov/pubmed/37431351
http://dx.doi.org/10.7759/cureus.40179

Ejemplares similares